7SEM image
Deposition Date 2021-09-30
Release Date 2022-02-16
Last Version Date 2024-11-20
Entry Detail
PDB ID:
7SEM
Title:
Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.20 Å
R-Value Free:
0.23
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:MPE8 Fab heavy chain
Chain IDs:A (auth: B)
Chain Length:228
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:MPE8 Fab light chain
Chain IDs:C
Chain Length:216
Number of Molecules:1
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Fusion glycoprotein F0
Chain IDs:B (auth: F)
Chain Length:551
Number of Molecules:1
Biological Source:Human metapneumovirus
Ligand Molecules
Primary Citation
Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins.
Nat Commun 13 1299 1299 (2022)
PMID: 35288548 DOI: 10.1038/s41467-022-28931-3

Abstact

The human metapneumovirus (hMPV) fusion (F) protein is essential for viral entry and is a key target of neutralizing antibodies and vaccine development. The prefusion conformation is thought to be the optimal vaccine antigen, but previously described prefusion F proteins expressed poorly and were not well stabilized. Here, we use structures of hMPV F to guide the design of 42 variants containing stabilizing substitutions. Through combinatorial addition of disulfide bonds, cavity-filling substitutions, and improved electrostatic interactions, we describe a prefusion-stabilized F protein (DS-CavEs2) that expresses at 15 mg/L and has a melting temperature of 71.9 °C. Crystal structures of two prefusion-stabilized hMPV F variants reveal that antigenic surfaces are largely unperturbed. Importantly, immunization of mice with DS-CavEs2 elicits significantly higher neutralizing antibody titers against hMPV A1 and B1 viruses than postfusion F. The improved properties of DS-CavEs2 will advance the development of hMPV vaccines and the isolation of therapeutic antibodies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures